Tagged with CEO

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Denmark Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years, LEO is now on the lookout for a replacement with capital market experience and the ability to steer the firm…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Denmark Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including deeper penetration of the US market, shifting from injections to tablets, and driving digitalisation and efficiency.   To put our…

Denmark GN Hearing CEO Gitte Aabo highlights the significant unmet needs of hearing impairment patients, the role of private companies like GN in fighting against stigmas surrounding hearing aids, the digital innovations occurring in the space, and her leadership strategy moving forward.   It takes an average of seven years for…

Denmark Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including deeper penetration of the US market, shifting from injections to tablets, and driving digitalisation and efficiency. Hellmann also outlines the…

Denmark Since joining Danish neuroscience specialist Lundbeck as its global CEO in 2018, South African Deborah Dunsire has focused on “revitalising and refreshing” the firm’s pipeline, which had seen several failures in the preceding years. In an exclusive recent conversation with PharmaBoardroom, Dunsire explains the strategy she has put in place…

Denmark Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to “revitalise and refresh” the Danish firm’s pipeline upon taking the role three years ago. Following two recent acquisitions, Lundbeck now has a much broader focus across neuroscience including areas for…

Singapore Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant transformation in its business approach, Queniart-Stojanovic is adapting this to the market realities in her managed countries as well as…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland CEO Tero Silvola introduces BC Platforms’ powerful data and technology platform for personalized medicine and drug development and the ‘infinity loop’ between the interconnected sectors of healthcare and life sciences that the company serves. Silvola also highlights how BC Platforms leverages the Swiss innovation ecosystem and why the next five…